Call (844) 879-2237

Home » News » Acera Surgical Announces Publication of Pre-Clinical Study on Restrata™

Acera Surgical Announces Publication of Pre-Clinical Study on Restrata™

St. Louis, MO—September 5, 2017— Acera Surgical Inc., a company dedicated to the development and commercialization of fully synthetic electrospun scaffolds for medical applications, announced today the publication of results from the pre-clinical study of the efficacy of Restrata Wound Matrix in the Cureus Journal of Medical Science.  Cureus Journal of Medical Science is a web-based peer-reviewed medical journal for a new generation of doctors and patients with global exposure.  Cureus article

The study, titled “Comparison of a Fully Synthetic Electrospun Matrix to a Bi-Layered Xenograft in Healing Full Thickness Cutaneous Wounds in a Porcine Model,” demonstrates RestrataTM’s ability to accelerate healing and closure of full-thickness wounds and to increase the amount and maturity of granulation tissue and neovascularization compared to a leading biologic skin substitute.

“Acera is excited to highlight the results of our preclinical study of the Restrata Wound Matrix product,” stated Dr. Matthew MacEwan, Chief Science Officer at Acera Surgical, Inc.  “Our findings highlight the ability of Restrata to improve the speed and quality of wound healing and reduce inflammation within the wound bed over an existing standard of care, all of which may result in significant clinical benefits for future patients treated with Restrata.”

The study results are also scheduled for a poster presentation at the Fall 2017 Symposium on Advanced Wound Care (“SAWC”), being held in Las Vegas, Nevada from October 20-22. SAWC is one of the nation’s largest and most well-respected interdisciplinary wound care programs.

About Acera Surgical Inc.

Acera Surgical Inc., (“Acera,” St. Louis, Missouri) is a bioscience company developing and commercializing a portfolio of fully synthetic electrospun scaffolds for medical applications. Acera’s products exhibit a structure similar to native extracellular matrix (ECM) and thus support rapid and effective healing. The FDA cleared Acera’s first product, Cerafix® Dura Substitute, in 2016 and its second product, RestrataTM Wound Matrix, in 2017, both via 510(k), granting commercial access to markets exceeding $1.2B in revenue.  Acera is currently raising Series A financing and seeking commercialization partners.

For additional information on Acera Surgical or the RestrataTM Wound Matrix, please visit



Comments are closed.